SAREPTA THERAP (AB3A BE) stock market data APIs
€18.0568
0(0%)
as of March 5, 2026
Try our APIs with
free plan!
SAREPTA THERAP Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for AB3A.BE.
Prev. Close
18.0568
Open
18.0568
High
18.0568
Low
18.0568
52 wk Range
9.55-64.44
Market Cap
6 592 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get SAREPTA THERAP data using free add-ons & libraries
Get SAREPTA THERAP Fundamental Data
SAREPTA THERAP Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
SAREPTA THERAP News
New
Sarepta CEO To Jump Ship After 'Tumultuous' Year
Sarepta Therapeutics, Inc.(NASDAQ:SRPT) shares are down during Thursday’s premarket session as the company reported its fourth-quarter and full-year 2025 financial results. Over the last year, the ...
Sarepta Q4 Loss Wider Than Expected, Sales Beat Estimates
Sarepta Therapeutics, Inc. SRPT reported a fourth-quarter 2025 adjusted loss of $3.58 per share, wider than the Zacks Consensus Estimate of a loss of 71 cents. This higher-than-anticipated loss was at...
Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress
Several abstracts, including a late-breaking podium presentation and posters, bring forward accumulating long-term efficacy, safety and caregiver-reported insights that deepen understanding of dystrop...
Sarepta Therapeutics Inc (SRPT) Q4 2025 Earnings Call Highlights: Strong Financial Position ...
This article first appeared on GuruFocus. Cash and Investments: $954 million at the end of 2025, with an increase of $89 million in the fourth quarter. Net Product Revenue for 2025: $1.86 billion, wi...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
